- A retrospective study suggests that BMI and basal levels of androstenedione are associated with risk for miscarriage in women with PCOS undergoing a gonadotropin-releasing hormone (GnRH)-antagonist protocol for in vitro fertilization (IVF).
Why this matters
- Both factors had moderate predictive ability on the miscarriage rate.
- The prognostic value of basal androstenedione was slightly stronger than that of BMI.
- Patients with overweight, hyperandrogenemia (HA) status had a higher miscarriage rate (45.2% vs 14.5%; P<.05 and a lower live birth rate vs compared with patients nonoverweight non-ha status.>
- BMI (OR, 1.097; P=.049) and basal androstenedione (OR, 1.071; P=.034) were independently associated with miscarriage rate in multivariate analysis.
- BMI >25.335 had an area under the curve of 0.607 (P=.029), a sensitivity of 51.1%, and a specificity of 73.7% for predicting miscarriage.
- Basal androstenedione >10.95 had an area under the curve of 0.657 (P=.001), a sensitivity of 72.3%, and a specificity of 58.4% for predicting miscarriage.
- 583 infertile women with PCOS who underwent IVF with a standard GnRH-antagonist protocol were analyzed for effects of BMI and androstenedione on pregnancy outcomes.
- Funding: National Natural Science Foundation of China.
- Retrospective study.